secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2025-06-30T23:59:59+00:00
Accession:  0000950170-25-091613
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics to present 8 abstracts at ENDO 2025, including long-term paltusotine data and Phase 2 CAH results
--------------------------------------------------------------------------------

- Eight abstracts at ENDO 2025 (July 12-15, San Francisco) covering PALSONIFY (paltusotine), atumelnant, and CRN12755.
- Oral presentation of long-term PATHFNDR-1 open-label extension data for paltusotine in acromegaly, showing durable biochemical and symptom control.
- Phase 2 open-label trial results for atumelnant in congenital adrenal hyperplasia featured as oral presentation; data on adrenal volume and androgen reductions.
- Early-stage pipeline data on CRN12755, a TSHR antagonist for Graves' hyperthyroidism and orbitopathy, also to be presented.
- PALSONIFY conditionally approved as trade name by FDA; atumelnant Phase 2 interim results show rapid reductions in androstenedione and 17-hydroxyprogesterone.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000095017025091613/0000950170-25-091613-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000095017025091613/crnx-20250630.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-091613

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer